Sign inJoin waitlistJoin the waitlist

Mary Tomayko

Director Yale Immunobullous Clinic, Dermatology · Yale-New Haven Hospital

Credentials: · · · ·

History

Medical Education · Yale-New Haven Hospital
Present
collaborative excellence and medical education · Yale School of Medicine
Present
Yale-New Haven Hospital · Yale School of Medicine
Present

Yale University School of Medicine
2004–2005
Yale University School of Medicine
2001–2004
Hospital of the University of Pennsylvania
1998–2001
Perelman School of Medicine at the University of Pennsylvania
Perelman School of Medicine at the University of Pennsylvania
1994–1998

Research

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
Nature Immunology · 2010 · 558 citations
CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype
Nature Immunology · 2014 · 386 citations
High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq
Nature Biotechnology · 2023 · 327 citations

Mark Shlomchik
10 papers
William Damsky
8 papers
DH
David Hafler
6 papers
Jonathan Leventhal
6 papers · 1 as a resident
Michael Kasperkiewicz
5 papers
Caroline Nelson
4 papers · 1 as a fellow
Donna Culton
4 papers
Stephanie Halene
4 papers
Erin Longbrake
3 papers
JG
Jeff Gehlhausen
3 papers · 3 as a resident
Jeffrey Cohen
3 papers
JC
Joseph Craft
3 papers

Grants

An Immunological Investigation of Meniere's Disease
National Institute on Deafness and Other Communication Disorders · R21
PI · $461.3K · Yale University
2025–2027
B Cell Memory Regulation by Bone Morphogenetic Protein Receptor 1A
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $2.2M · Yale University
2015–2021
Elucidating Functional Properties of Memory B Cells
National Institute of Allergy and Infectious Diseases · K08
Contact PI · $773.7K · Yale University
2008–2013

Clinical trials

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Site PI · Recruiting · Phase 1, Phase 2
Cabaletta Bio
2020–2029